Reporter gene construct for the detection of HIV rev and HIV tat
    1.
    发明公开
    Reporter gene construct for the detection of HIV rev and HIV tat 审中-公开
    Reporterkonstrukt zur Detektion von HIV rev and HIV tat

    公开(公告)号:EP1270744A1

    公开(公告)日:2003-01-02

    申请号:EP02013820.2

    申请日:2002-06-21

    IPC分类号: C12Q1/68 C12N15/86

    摘要: The present invention relates to a reporter gene construct for the detection of the HIV Rev and HIV Tat proteins. Furthermore, the invention relates to a functionality test method for Rev and Rev fusion proteins prepared in a recombinant manner, a method of screening for sequences of different origin for their activity as an instability element, a method of screening for sequences which cause the transport out of the nucleus into the cytoplasm by binding to cellular or other viral shuttle proteins, as well as to a method for the detection of HIV-infected cells. The reporter gene construct according to the present invention, after it has been introduced into cells, in the presence of HIV Rev and HIV Tat proteins results in the formation of reporter proteins which may be used for quantitative/qualitative detection of the HIV Rev and HIV Tat proteins.

    摘要翻译: 本发明涉及用于检测HIV Rev和HIV Tat蛋白的报告基因构建体。 此外,本发明涉及以重组方式制备的Rev和Rev融合蛋白的功能性测试方法,筛选不稳定因子作为不稳定性元件的活性的不同来源序列的方法,筛选引起转运的序列的方法 通过与细胞或其他病毒穿梭蛋白结合而进入细胞质,以及用于检测HIV感染细胞的方法。 根据本发明的报告基因构建体在其被引入细胞之后,在HIV Rev和HIV Tat蛋白的存在下导致报道蛋白的形成,其可用于HIV Rev和HIV的定量/定性检测 Tat蛋白。

    Orthopoxvirus antigens and use thereof
    10.
    发明公开
    Orthopoxvirus antigens and use thereof 审中-公开
    Antigene des Orthopoxvirus und ihre Verwendung

    公开(公告)号:EP1398380A1

    公开(公告)日:2004-03-17

    申请号:EP02022252.7

    申请日:2002-10-02

    摘要: The present invention is directed to a method of detecting a T cell response induced by smallpox vaccines or Orthopoxvirus vector vaccines in a mammal and to immunogenic Orthopoxvirus antigens and the nucleic acids encoding same. The present invention further relates to pharmaceutical compositions and their use in the protective immunization against a smallpox infection.

    摘要翻译: 包含其中一个肽(P1)的免疫原性正痘病毒抗原(I),其具有选自50个氨基酸序列或其变体的序列,其包含与各自(P1)相比的一个或多个添加,插入,取代和/或缺失, 该变体的免疫原性活性基本上等于相应未修饰(P1)的活性,是新的。 包含至少一种肽(P1)的免疫原性正痘病毒抗原(I),其具有选自50个氨基酸序列的序列,例如 (Ⅰa)或其变体包含与各自(P1)相比的一个或多个添加,插入,取代和/或缺失,并且其中变体的免疫原性活性基本上等于相应未修饰(P1)的活性, 。 Ile-Ile-Ala-Ile-Val-Phe-Val-Phe-Ile-Leu(Ia)Tyr-Leu-Asp-Asn-Leu-Leu-Pro-Ser-Thr-Leu(Ib)Phe-Ile-Leu- Thr-Ala-Ile-Leu-Phe-Leu(Ic)Tyr-Leu-Asp-Asn-Leu-Leu-Pro-Ser-Thr(Id)Gly-Leu-Ile-Ile-Ile-Ser-Ile-Phe- Leu(Ie)Ile-Ile-Ile-Ser-Ile-Phe-Leu-Gln-Val(If)Phe-Ala-Ile-Ile-Ala-Ile-Val-Phe-Val(Ig)Tyr-Leu-Phe- Arg-Ile-Val-Ser-Thr-Val(Ih)Leu-Leu-Asn-Asn-Ser-Leu-Gly-Ser-Val(Ii)Asn-Leu-Ala-Thr-Ser-Ile-Tyr-Thr- Ile(Ij)独立权利要求也包括:(1)分离的核酸(II),其编码(P1)中的一个或多个; (2)分离的核酸(III),其是(II)的转录产物; (3)分离的核酸(IV),其在中等严格条件下与(II)或(III)选择性杂交; (4)由(II),(III)或(IV)编码的免疫原性抗原(V); (5)载体(VI),其包含一种或多种(II),(III)或(IV)的核酸序列; (6)包含一种或多种(II),(III)或(IV)的核酸序列和一种或多种调节序列的表达载体(VII) (7)用(VI)或(VII)转化的宿主细胞(VIII); (8)已经用(P1)中的一种或多种脉冲的抗原呈递细胞(APC); (9)包含(P1)和/或APC中的一种或多种的诊断组合物(C1) (10)用于检测由包含至少一种或多种(P1)或APC的天花疫苗或正痘病毒载体疫苗诱导的免疫应答的诊断试剂盒(K1) 和(11)包含(P1),(II),(III)或(IV)或(VI)或(VII)中的一种或多种的载体的组合物(C2)。 活动:病毒。 没有给出生物数据。 动作机制:疫苗。 没有给出生物数据。